<div id="readability-page-1"><div>** Shares of drug developer AC Immune soar 45.9% to $4.07 premarket ** Co says its treatment for Parkinson's disease showed positive safety and efficacy results in a mid-stage trial ** Parkinson's disease is a movement disorder of the nervous system that worsens over time ** Co says the therapy, ACI-7104.056, induced a robust antibody response against the immunizing a-syn target antigen ** The therapy also showed stabilization of disease-relevant biomarkers in the central nervous system, suggesting slowing of Parkinson's disease- ACIU ** ACI-7105.056 is generally safe and well-tolerated, co says ** Co to seek regulatory feedback on ACI-7104.056 to potentially accelerate towards registration** Up to last close, stock up 3.3% YTD </div></div>

ACIU

AC Immune's shares surged 45.9% premarket after its Parkinson's treatment, ACI-7104.056, showed positive safety and efficacy in a mid-stage trial. The treatment induced a strong antibody response and stabilized disease-relevant biomarkers, suggesting a slowing of Parkinson's progression. The company plans to seek regulatory feedback to potentially accelerate registration. Prior to this, the stock was up 3.3% year-to-date.

AC Immune jumps after Parkinson's treatment shows promise in mid-stage study